🔎 Trials Near Me

Home › Leucemia mieloide acuta › Illinois › Chicago

Studi clinici su Leucemia mieloide acuta a Chicago, IL

26 studi su Leucemia mieloide acuta cercano partecipanti presso sedi a Chicago e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

In reclutamentoStudio osservazionaleVolontari sani benvenuti
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • e altri 1
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

In reclutamentoFase 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Età da 18 a 59 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

In reclutamentoFase 3
  • University of Chicago Medicine, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • e altri 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

In reclutamentoFase 1
  • Lurie Children's Hospital-Chicago, Chicago
Fino a 21 anni · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Età da 18 a 59 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

In reclutamentoFase 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
6 Months – 21 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

In reclutamentoFase 1/2
  • The University of Chicago Medical Center, Chicago
30 Days · Tutti i sessi · Aggiornato il 16 set 2026 · NCT04065399

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

In reclutamentoFase 1/2
  • University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 set 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

In reclutamentoFase 3
  • Lurie Children's Hospital-Chicago, Chicago
Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07022678

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

In reclutamentoFase 3
  • US-Chigago IL-UHCHICAGO, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07223814

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

In reclutamentoFase 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

In reclutamentoFase 3
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
  • Comer Children's Hospital, Chicago
29 Days – 21 Years · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

In reclutamentoFase 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

In reclutamentoStudio osservazionale
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • e altri 2
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

In reclutamentoFase 1
  • University of Chicago, Chicago
Età 13 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

In reclutamentoFase 1/2
  • Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 apr 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

In reclutamentoFase 1/2
  • Northwestern, Chicago
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

In reclutamentoFase 1
  • Northwestern Medicine, Chicago
Età 12 e oltre · Tutti i sessi · Aggiornato il 16 mar 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

In reclutamentoFase 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mar 2026 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

In reclutamentoFase 1
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2025 · NCT06501196

Studi su Leucemia mieloide acuta in altre città

Altri studi a Chicago

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.